190 results on '"Steegmann, J"'
Search Results
2. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
3. Is there an ideal way to close the donor site of radial forearm free flaps?
4. Preoperative assessment of the risk of postoperative death in patients with oral squamous cell carcinoma: a consideration beyond age, sex, and stage of cancer
5. Sportwissenschaft
6. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
7. Reply to Constance et al.
8. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
9. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
10. Interferon-α2a in the Treatment of Chronic Myeloid Leukemia: Results of the Spanish Group on Interferon-α2a in CML
11. Erythropoietin Treatment in Allogeneic Bone Marrow Transplantation: A Prospective and Randomized Trial
12. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
13. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey
14. Multiple eruptive dermatofibromas related to imatinib treatment
15. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
16. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes
17. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
18. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
19. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation
20. “FlapApp” – contemporary microvascular free flap surveillance
21. Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients
22. Imatinib Mesylate Induces Hypophosphatemia in Patients With Chronic Myeloid Leukemia in Late Chronic Phase, and This Effect is Associated With Response
23. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses
24. Cutaneous presentations of cryptoccocosis
25. SUSPENSION OF TREATMENT WITH BCR-ABL INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE WITHIN OF THE CLINICAL ASSISTANCE PRACTICE: SPANISH EXPERIENCE IN A TOTAL OF 236 CASES
26. Virtual reality in preoperative imaging in maxillofacial surgery: implementation of “the next level”?
27. PB2230 SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB-OZOGAMICIN
28. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
29. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
30. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
31. The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases
32. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials
33. Moderne Gesichtsprotektionsmasken im Profi-Ballsport – eine Fallstudie
34. Reply to Constance et al.
35. ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY
36. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
37. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
38. The EUTOS population-based registry : incidence and clinical characteristics of 2904 CML patients in 20 European Countries
39. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials
40. Evaluation der Roboterassistenz im Bereich Frontobasis- bzw. transsphenoidalen Schädelbasischirurgie
41. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
42. The Eutos Population-Based Registry : Evaluation of Baseline Characteristics and First Treatment Choices Of 2983 Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients from 20 European Countries
43. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders
44. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
45. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey
46. Prevalence and management of anemia in patients with non-myeloid tumors undergoing systemic therapy.
47. Imatinib use in chronic phase CML in clinical practice: the UNIC study
48. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses
49. The direct antiglobulin test is frequently positive in chronic myeloid leukemia patients treated with interferon‐α
50. ERYTHROPOIETIN TREATMENT AND PLATELET RECONSTITUTION IN BONE MARROW TRANSPLANTATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.